• Skip to primary navigation
  • Skip to content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Business Directory
    • Buyers | Licensees
    • Sellers | Ancillary Businesses
    • Submit Product & Service Press Release
  • CBE Exchange
  • CBE Jobs Exchange
  • Events
  • Featured Videos
  • Product & Service Press Releases
  • Sponsored Polls
  • Webinars
    • Upcoming Webinars
    • Archived Webinars
  • Whitepapers

Cannabis Business Executive - Cannabis and Marijuana industry news

Recreational, Medical, Marijuana, Cannabis, And Hemp News for Cannabis Businesses

  • Follow on Facebook
  • Follow on Twitter
  • Follow on Google+
  • Follow on LinkedIn
  • Subscribe to our RSS feed
Newsletter 2
  • Home
  • Policy & Legal
    • Hemp Business Executive
    • International
      • Canada
      • Mexico
      • Israel
    • US A to F
      • Alabama
      • Alaska
      • Arizona
      • Arkansas
      • California
      • Colorado
      • Connecticut
      • Delaware
      • District of Columbia
      • Florida
    • US G to M
      • Georgia
      • Hawaii
      • Illinois
      • Indiana
      • Idaho
      • Iowa
      • Kansas
      • Kentucky
      • Louisiana
      • Maine
      • Maryland
      • Massachusetts
    • US M to N
      • Michigan
      • Minnesota
      • Mississippi
      • Missouri
      • Montana
      • Nebraska
      • Nevada
      • New Hampshire
      • New Jersey
      • New Mexico
      • New York
      • North Carolina
      • North Dakota
    • US O to V
      • Ohio
      • Oklahoma
      • Oregon
      • Pennsylvania
      • Rhode Island
      • South Carolina
      • South Dakota
      • Tennessee
      • Texas
      • Utah
      • Vermont
    • US V to W
      • Virginia
      • Washington
      • Wisconsin
      • Wyoming
      • Guam
      • Puerto Rico
  • News & Insights
    • Advertising, Marketing, PR & Research
    • Banking, Finance & Real Estate
    • Compliance and Regulations
    • Corporate Social Responsibility
    • Retailers
    • Hemp Business Executive
    • HR and Staffing
    • North Of The Border
    • Industry People/On the Move
    • Packaging and Supplies
    • Press Releases
    • Processors
    • Producers
    • Security Solutions
    • Science and Technology
    • South Of The Border
  • CBE Lists
    • Ancillary Businesses
      • 2019 CBE Ancillary Business Survey CLICK HERE
      • 2018 CBE 155 A/B
      • 2017 CBE 150 A/B
      • 2016 CBE 100 A/B
    • Producers, Processors, Retailers
      • 2017 CBE 200 PPRs
      • 2015 CBE 100 PPRs
    • Industry Women
      • Glass Ceiling Wreckers: 2019 CBE Power Women of Cannabis
      • 2017 CBE 75 Most Important Women
      • 2016 CBE Top 50 Women
      • 2014 CBE Most Influential Women
    • Most Important Companies
      • 2016 CBE 10 Most Important Companies
      • 2014 CBE 10 Most Important Companies
    • Political 100
      • 2017 CBE Political 100
      • 2016 CBE 100 Political
      • 2014 CBE Political 50
    • 2014 CBE 100 Most Important People
    • CBE RFP Hotlists
      • 2014 CBE Lab Testing Services HotList
      • 2016 BHO Extraction Equipment
      • 2016 CBE Supercritical CO2 Extraction Equipment
      • 2016 CBE Security Solutions
      • 2016 Edibles & Infused Products
  • Company Stories
    • Up and Comers
  • Hemp Business Executive
    • Hemp Policy & Legal
    • Hemp Industry News
    • Hemp State Regulatory Agencies
  • Newsletters
    • CBE News & Insights (Formerly CBE Week)
    • CBE Human Capital Management
    • CBE Technology & Solutions
    • CBE Policy and Legal
    • CBE Product and Service Announcements
  • Op-Ed
    • Cartoons
    • The Buck Stops Here
    • Opinions
    • Comments
  • Associations
  • State Regulatory Agencies
    • Marijuana
    • Hemp
  • Contact
  • AB Survey
  • About Us
  • Account
  • Accounting Services
  • Advertise
  • Advertising, PR & Marketing
  • All Cannabis News
  • Ancillary Business Survey 2018
  • Ancillary Business Survey 2019
  • Archived Webinars
  • Associations & Organizations
  • Banking & Payment Processing
  • Better Start for the Glass Ceiling in this Industry, CBE’s Most Influential Women
  • Book Reviews
  • Business Directory
  • Business Directory Introduction
  • Business Directory Listing
  • Business Directory Manage
  • Business Directory Registration Info
  • Business Directory Welcome
  • Call for speakers
  • Cannabis Investments
  • Cart
  • CBE Exchange
  • CBE HotLists
    • CBE Lab Testing Services HotList 2014
  • CBE Lists
  • CBE Political 50
  • CBE Press LLC Privacy Statement
  • CBE Press News
  • Checkout
  • Consulting Services
  • Consumption Gear
  • Contact
  • Contribute
  • Contributors
  • Create Your Product & Service Press Release
  • Creative Submission
  • Cultivation Products & Services
  • Current Poll
  • Edible & Infused Products
  • Editor’s Page
  • Email Whitelisting Instructions
  • Event Listing Questionaire
  • Featured Videos
  • Funding Options
  • Hemp State Regulatory List
  • Home
  • Human Capital Management Newsletters
  • Industry Jobs
  • Join the CBE Business Directory
  • Join the Directory
  • Lab Testing Regulations
  • Lab Testing Services
  • Login
  • Logout
  • Marijuana State Regulatory Contacts
  • Marijuana Tax Facts
  • Media Kit
  • Media Kit
  • Medical Marijuana Qualifying Conditions
  • Members
  • MJ Media Kit
  • Most Popular Stories
  • Most Read Stories
  • New Product & Service Listings Welcome
  • Newsletters
    • Ask CBE
    • CBE Human Capital Management
    • CBE News & Insights (Formerly CBE Week)
    • CBE Policy and Legal
    • CBE Product and Service Announcements
    • CBE Technology & Solutions
  • On the Move
  • Organizations & Associations
  • Packaging & Supplies
  • Password Reset
  • Policy & Legal
  • PPR Survey
  • PR Newswire
  • Product Releases
  • Profile Update
  • Register
  • Security Solutions
  • Software & Technology
  • Sponsored Polls
  • State Cannabis Product Packaging Requirements
  • Terms of Service
  • Thank You
  • The Most Influential People in the Cannabis Industry, The Cannabis Business Executive 100
  • Training & Educational Services
  • Upcoming Webinars
  • User
  • Whitepapers
  • WV Senate passes medical marijuana bill to House
  • Categories
  • Locations
  • My Bookings
You are here: Home / Hemp Business Executive / Hemp Policy & Legal / Not All CBD Health Claims Are Treated Equal

Not All CBD Health Claims Are Treated Equal

June 3, 2020 by AggregatedNews Leave a Comment

By Natalie Bougenies, Attorney at Harris Bricken

If you read this blog and keep a close eye on the cannabidiol (“CBD”) industry, you know that the Federal Trade Commission (“FTC”)  takes issue with advertising tools containing egregious, unfounded claims about the health benefits of CBD products. Yet, you might be surprised to read that the federal agency does not go after every actor that promotes the therapeutic value of these products. This post explains why.

The FTC is empowered under the Federal Trade Commission Act (“FTC Act”) to regulate advertising to protect the public from unfair and deceptive claims made in any medium. Under the FTC Act, companies must support their advertising claims with solid evidence. This is especially true for businesses that market food, dietary supplements, and other health-related products. The objective of the FTC is to ensure that consumers get accurate information about these products so they can make informed decisions.

In reviewing health claims, the FTC gives great deference to the Food and Drug Administration (“FDA”) – the agency tasked with regulating these products. The FTC follows the FDA’s determination of whether there is adequate support for a health claim to be made.

As we have written at length, the FDA treats any CBD products marketed as having therapeutic value as a drug. Drugs are tightly regulated and subject to FDA pre-approval for safety and effectiveness purposes before introduction into interstate commerce. With the exception of Epidiolex, no product containing hemp CBD has been approved as safe and effective for medical use.

Accordingly, to align with this FDA policy, the FTC mandates that any person who makes any health benefit claim about CBD products must possess and rely upon “competent and reliable scientific evidence.” In simple terms, “competent and reliable scientific evidence” means tests, analyses, research, and studies conducted and evaluated by experts in the field that substantiate that the representation is true. Yet, given the limited number of scientific studies on the health benefits of CBD, virtually no advertiser making medical claims about these products could possibly defend its representations under the federal standards.

These standards, however, only apply to people directly involved with the advertising of these products. This means that independent consumer reviews, which are reviews made by individuals who have no connection to the product manufacturer or distributor, are exempt from such regulations. This explains why publications like Forbes and Vogue frequently release articles ranking “best CBD products,” which are filled with all kinds of medical claims.

This, of course, is premised on the assumption that these publications and their journalists are expressing their personal opinion and fondness for a particular CBD product and have no endorsement deal with any of the CBD companies whose products they are reviewing.

If these publications and journalists did have some sort of sponsorship or endorsement deal –  let’s say, the journalists receive free CBD products from the company, then these journalists and the CBD companies would be subject to the FTC rules and would need to disclose their relationship. Regulators would view the journalists as part of the CBD company’s marketing program, which is essential in helping consumers evaluate the review and the quality of the product. In addition, the company would need to ensure that the journalists do not make any health claims that would open them up to enforcement actions by the FTC, which are no longer limited to issuing warning letters.

In sum, honest, independent consumer assessments, including online reviews, social media posts and video, fall outside the jurisdiction of the FTC, even if they contain health claims otherwise punishable if made by CBD companies. The primary goal of the FTC is to protect the public from deceiving companies which hold a financial interest in a product, not to silence people’s free speech.

Re-published with the permission of Harris Bricken and The Canna Law Blog

 

Contextual Links

Filed Under: Hemp Policy & Legal Tagged With: CBD, false advertising claims, Federal Trade Commission (“FTC”), Food & Drug Administration (FDA)

Primary Sidebar

Ad: Sidebar 1

Featured Video

Associations & Organizations

clearing div

Ad: Sidebar 2

Business Directory

Ad: Skyscraper 1

CBE Jobs Exchange


Featured Jobs
Go
Post a Job
More jobs
Powered by CBEJobsExchange.com

RSS Recent Jobs

  • Senior Account Executive (Marketing & PR) - Acceleration Community of Companies - Los Angeles, CA
  • Administrative Law Judge - Temporary Appointment - WA State: Office of Administrative Hearings - Multiple Locations Statewide, WA
  • Senior Research Biostatistician - TSET Health Promotion Research Center at Stephenson Cancer Center/OUHSC - Oklahoma City, OK

Product & Service Press Releases

Ad: Sidebar 3

CBE Events

Ad: Sidebar 4

State Regulatory Agencies

Ad: Skyscraper 2

Webinars

Ad: Sidebar 5

Associations & Organizations

Ad: Sidebar 6

Featured Video

Ad: Skyscraper 3

Business Directory

Ad: Sidebar 7

CBE Jobs Exchange

Ad: Sidebar 8

CBE Events

Ad: Skyscraper 4

Footer

  • Home
  • About Us
  • Advertise
  • Contact
  • CBE Press LLC Privacy Statement
  • Contribute
  • Contributors
  • Newsletters
  • Terms of Service
  • Contributor Login
  • Follow on Facebook
  • Follow on Twitter
  • Follow on Google+
  • Follow on LinkedIn
  • Subscribe to our RSS feed
Newsletter 2

© Copyright 2020 CBE PRESS LLC. - All Rights Reserved. Cannabis Business Executive Is A Trademark Of CBE PRESS LLC. · All Rights Reserved · And Our Sitemap · All Logos & Trademarks Belong To Their Respective Owners·